Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ADAMTS5 | Q9UNA0 | 6/20 | 0.31 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | RGS12 | O14924 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.30 |
| ▸ | MMP12 | P39900 | 1/20 | 0.30 |
| ▸ | ADAM9 | Q13443 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13644706 | 1.00 | TSHR (0.43) | TSHRGAAALDH1A1KMT2AMEN1 | |
| SCHEMBL30684676 | 0.83 | TSHR (0.40) | TSHRGAAALDH1A1KMT2AMEN1 | |
| SCHEMBL21325387 | 0.77 | TSHR (0.41) | TSHRGAAALDH1A1KMT2AMEN1 | |
| SCHEMBL191784 | 0.75 | — | — | |
| SCHEMBL17830362 | 0.75 | — | — | |
| SCHEMBL12011156 | 0.75 | — | — | |
| SCHEMBL11352404 | 0.74 | TSHR (0.46) | TSHRGAAALDH1A1KMT2AMEN1 | |
| SCHEMBL1833750 | 0.73 | GAA (0.43) | TSHRGAAALDH1A1KMT2AMEN1 | |
| SCHEMBL12344339 | 0.72 | GAA (0.46) | TSHRGAAALDH1A1KMT2AMEN1 | |
| SCHEMBL854739 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-7274985-A | — | — | None | — | — | JP | disclosed |
| US-10011574-B2 | Glutaminase inhibitors and method of use | AGIOS PHARMACEUTICALS, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-10011574-B2 | Glutaminase inhibitors and method of use | AGIOS PHARMACEUTICALS, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-9303002-B2 | Compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20150299152-A1 | GLUTAMASE INHIBITORS AND METHOD OF USE | SERVIER PHARMACEUTICALS LLC | 2015-10-22 | — | — | US | disclosed |
| US-20140142146-A1 | COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2014-05-22 | — | — | US | disclosed |
| US-20090264384-A1 | INDOLE, BENZIMIDAZOLE, AND BENZOLACTAM BORONIC ACID COMPOUNDS, ANALOGS THEREOF AND METHODS OF USE THEREOF | NUADA, INC. (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090005344-A1 | Compounds and Methods of Use Thereof | NKUADA, LLC (US) | 2009-01-01 | — | — | US | disclosed |
| US-20090005344-A1 | Compounds and Methods of Use Thereof | NKUADA, LLC (US) | 2009-01-01 | — | — | US | disclosed |
| US-20080319044-A1 | Compounds and Methods of Use Thereof | NUADA, LLC (US) | 2008-12-25 | — | — | US | disclosed |
| JP-H07274985-A | PRODUCTION OF D-GAMMA-METHYLLEUCINE | MITSUBISHI CHEM CORP | 1995-10-24 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011574-B2 | Glutaminase inhibitors and method of use | GLS, GLS2, GLUL | TSHR 4186/4885GAA 29/4885ALDH1A1 553/4885 |
| US-20090005344-A1 | Compounds and Methods of Use Thereof | TNF, IL1B, TNFRSF1A | TSHR 2492/4885GAA 178/4885ALDH1A1 830/4885 |
| US-20150299152-A1 | GLUTAMASE INHIBITORS AND METHOD OF USE | GLS, GLS2, GLUL | TSHR 4337/4885GAA 24/4885ALDH1A1 706/4885 |
| US-20090264384-A1 | INDOLE, BENZIMIDAZOLE, AND BENZOLACTAM BORONIC ACID COMPOUNDS, ANALOGS THEREOF AND METHODS OF USE THEREOF | TNF, NFKBIA, IL6 | TSHR 2514/4885GAA 925/4885ALDH1A1 531/4885 |
| US-20080319044-A1 | Compounds and Methods of Use Thereof | TNF, LITAF, LTA | TSHR 2000/4885GAA 1092/4885ALDH1A1 1349/4885 |
| US-20140142146-A1 | COMPOUNDS AND THEIR METHODS OF USE | GLS, GLS2, GLUL | TSHR 4360/4885GAA 19/4885ALDH1A1 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.